DMC Biotechnologies, Inc. (DMC; Boulder, Colo.; www.dmcbio.com) has successfully demonstrated full commercial scale (85 m3) fermentation for its first product, the amino acid L-alanine. The scaleup results identically tracked the performance at bench and pilot scales, further validating the predictability and scalability of DMC’s Dynamic Metabolic Control technology, the company says. Commercial performance metrics were demonstrated, meaning that no further strain improvements are required to achieve the target selling price.
This demonstration of process robustness and predictability across scale of production — from high-throughput screening to full commercial scale — has never been demonstrated in the field and represents a major advancement for DMC. This core technology enablement will also be beneficial for DMC’s pipeline of products that will be scaled and commercialized next.
The scale-up process was conducted at the Leuna facility of EW Biotech GmbH (Leuna, Germany; www.ew-biotech.com).